These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2175179)

  • 1. Effects of herbimycin A and various SH-reagents on p60v-src kinase activity in vitro.
    Fukazawa H; Mizuno S; Uehara Y
    Biochem Biophys Res Commun; 1990 Nov; 173(1):276-82. PubMed ID: 2175179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro.
    Fukazawa H; Li PM; Yamamoto C; Murakami Y; Mizuno S; Uehara Y
    Biochem Pharmacol; 1991 Oct; 42(9):1661-71. PubMed ID: 1656993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Labeling of v-Src and BCR-ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanism.
    Fukazawa H; Uehara Y; Murakami Y; Mizuno S; Hamada M; Takeuchi T
    FEBS Lett; 1994 Mar; 340(3):155-8. PubMed ID: 8131836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herbimycin A inhibits the association of p60v-src with the cytoskeletal structure and with phosphatidylinositol 3' kinase.
    Hamaguchi M; Xiao H; Uehara Y; Ohnishi Y; Nagai Y
    Oncogene; 1993 Mar; 8(3):559-64. PubMed ID: 8382356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds.
    Uehara Y; Fukazawa H; Murakami Y; Mizuno S
    Biochem Biophys Res Commun; 1989 Sep; 163(2):803-9. PubMed ID: 2783121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases.
    Uehara Y; Fukazawa H
    Methods Enzymol; 1991; 201():370-9. PubMed ID: 1658554
    [No Abstract]   [Full Text] [Related]  

  • 7. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system.
    Hamaguchi M; Matsuyoshi N; Ohnishi Y; Gotoh B; Takeichi M; Nagai Y
    EMBO J; 1993 Jan; 12(1):307-14. PubMed ID: 8381351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of reversion of Rous sarcoma virus transformation by herbimycin A: reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60v-src1.
    Uehara Y; Murakami Y; Sugimoto Y; Mizuno S
    Cancer Res; 1989 Feb; 49(4):780-5. PubMed ID: 2463877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of hsp 72/73 by herbimycin A, an inhibitor of transformation by tyrosine kinase oncogenes.
    Murakami Y; Uehara Y; Yamamoto C; Fukazawa H; Mizuno S
    Exp Cell Res; 1991 Aug; 195(2):338-44. PubMed ID: 2070817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. v-Src suppresses SHPS-1 expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells.
    Machida K; Matsuda S; Yamaki K; Senga T; Thant AA; Kurata H; Miyazaki K; Hayashi K; Okuda T; Kitamura T; Hayakawa T; Hamaguchi M
    Oncogene; 2000 Mar; 19(13):1710-8. PubMed ID: 10763828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of herbimycin derivatives on src oncogene function in relation to antitumor activity.
    Uehara Y; Murakami Y; Suzukake-Tsuchiya K; Moriya Y; Sano H; Shibata K; Omura S
    J Antibiot (Tokyo); 1988 Jun; 41(6):831-4. PubMed ID: 3403381
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence for autoinhibitory regulation of the c-src gene product. A possible interaction between the src homology 2 domain and autophosphorylation site.
    Fukami Y; Sato K; Ikeda K; Kamisango K; Koizumi K; Matsuno T
    J Biol Chem; 1993 Jan; 268(2):1132-40. PubMed ID: 7678249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oncogenic protein p60v-src has competence activity but does not activate phosphatidylinositol turnover or protein kinase C in Balb/c 3T3 cells.
    Han JW; Gaut J; Burstein E; Sadowski H; Young D; Macara IG
    Oncogene; 1990 Apr; 5(4):467-74. PubMed ID: 2158036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clustered cysteine residues in the kinase domain of v-Src: critical role for protein stability, cell transformation and sensitivity to herbimycin A.
    Senga T; Miyazaki K; Machida K; Iwata H; Matsuda S; Nakashima I; Hamaguchi M
    Oncogene; 2000 Jan; 19(2):273-9. PubMed ID: 10645006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cysteine residues in the C-terminal lobe of Src: their role in the suppression of the Src kinase.
    Oo ML; Senga T; Thant AA; Amin AR; Huang P; Mon NN; Hamaguchi M
    Oncogene; 2003 Mar; 22(9):1411-7. PubMed ID: 12618767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A.
    Uehara Y; Murakami Y; Mizuno S; Kawai S
    Virology; 1988 May; 164(1):294-8. PubMed ID: 2452516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction by herbimycin A of contact inhibition in v-src-expressed cells.
    Suzukake-Tsuchiya K; Moriya Y; Hori M; Uehara Y; Takeuchi T
    J Antibiot (Tokyo); 1989 Dec; 42(12):1831-7. PubMed ID: 2559910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells.
    Okabe M; Uehara Y; Noshima T; Itaya T; Kunieda Y; Kurosawa M
    Leuk Res; 1994 Nov; 18(11):867-73. PubMed ID: 7967714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts.
    Matsuyoshi N; Hamaguchi M; Taniguchi S; Nagafuchi A; Tsukita S; Takeichi M
    J Cell Biol; 1992 Aug; 118(3):703-14. PubMed ID: 1639852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo.
    Yoneda T; Lowe C; Lee CH; Gutierrez G; Niewolna M; Williams PJ; Izbicka E; Uehara Y; Mundy GR
    J Clin Invest; 1993 Jun; 91(6):2791-5. PubMed ID: 8514886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.